35 results on '"Kasserra, Claudia"'
Search Results
2. No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
3. Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug–drug interaction potential in vitro and in healthy subjects
4. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
5. Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function
6. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
7. Pharmacokinetic Interaction of Vicriviroc with Other Antiretroviral Agents: Results from a Series of Fixed-Sequence and Parallel-Group Clinical Trials
8. Renal Insufficiency Has No Effect on the Pharmacokinetics of Vicriviroc in a Ritonavir-Containing Regimen
9. Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men
10. Erratum to: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
11. Foraging activity of two species of predatory leeches exposed to active and sedentary prey
12. Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus
13. MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment
14. Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects
15. MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis.
16. MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment
17. Evaluation Of CYP450 and Transporter-Mediated Drug-Drug Interaction Potential Of Pomalidomide In Healthy Men and In Vitro
18. Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus
19. Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QT c Intervals in the Thorough QT c Study Conducted in Healthy Men
20. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).
21. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
22. Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein
23. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects
24. Precision and Accuracy in the Quantitative Analysis of Biological Samples by Accelerator Mass Spectrometry: Application in Microdose Absolute Bioavailability Studies
25. Effect of Boceprevir on Red Blood Cells and Markers of Anemia in Healthy Volunteers
26. Effect of Vicriviroc on the QT/Corrected QT Interval and Central Nervous System in Healthy Subjects
27. Short-Term Administration of the CCR5 Antagonist Vicriviroc to Patients With HIV and HCV Coinfection Is Safe and Tolerable
28. Myocardial oxygenation in vivo: optical spectroscopy of cytoplasmic myoglobin and mitochondrial cytochromes
29. The Effects of Skeletal Muscle Contractions and Paralysis on Physiological Responses to Head Immersion in Pekin Duck
30. Evaluation of methemoglobin as an autologous intravascular MRI contrast agent
31. Absorption, metabolism and excretion of [C]pomalidomide in humans following oral administration.
32. Precision and Accuracy in the Quantitative Analysis of Biological Samples by Accelerator Mass Spectrometry: Application in Microdose Absolute Bioavailability Studies.
33. Effect of externally applied bunker fuel on body mass and temperature, plasma concentration, and water flux of Glaucous-winged Gulls, Larus glaucescens
34. Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein.
35. Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.